麦科奥特MT2004核心专利获欧洲授权，全球知识产权壁垒再筑新高

MICOT

盐与晶型研究是药物成药性与制剂开发的核心技术环节，直接决定活性成分的稳定性、溶解度及生物利用度。作为化合物专利之后最重要的二次专利类型，盐与晶型专利构筑了更具体的核心技术屏障。本次授权的专利覆盖了特定FXR激动剂在胆汁淤积及肝保护相关适应症中的具体应用形式，进一步夯实了公司First-in-class候选药物的核心技术优势与差异化竞争壁垒。

在创新药全球化竞争日益加剧的背景下，海外专利布局是生物医药企业实现跨境临床、国际技术合作及未来市场独占的核心基础。此次欧洲专利的成功授权，不仅显著增强了MT2004项目的技术护城河，也为后续制剂开发、工艺优化及欧洲市场独占权维护提供了强有力的法律保障，显著提升了该管线的国际竞争力与商业价值。

MT2004项目已同步获得中国与美国的临床试验许可，并顺利完成临床I期研究。目前，该项目正在国内积极推进临床II期研究，重点适应症为胆汁淤积型及混合型药物性肝损伤（DILI）。

Salt and crystal form studies are critical for druggability and formulation development, directly impacting stability, solubility, and bioavailability. As the most important secondary patent type after the compound patent, this granted patent covers specific application forms of an FXR agonist for cholestasis and liver protection, further strengthening the core technological advantages and competitive barriers of this first-in-class candidate.

In the context of intensifying global competition, overseas patent protection is essential for cross-border clinical trials, international partnerships, and market exclusivity. The European patent grant significantly strengthens the technical moat of MT2004, offers legal safeguards for formulation development and process optimization, and enhances the project's international competitiveness and commercial value.

MT2004 has received clinical trial approvals in China and the United States, with Phase I studies successfully completed. The project is currently advancing into Phase II studies in China, focusing on cholestatic and mixed drug-induced liver injury (DILI).